<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107843</url>
  </required_header>
  <id_info>
    <org_study_id>7715</org_study_id>
    <nct_id>NCT05107843</nct_id>
  </id_info>
  <brief_title>Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas</brief_title>
  <acronym>SARCOMAS</acronym>
  <official_title>Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas - Single-center Pilot Study of 32 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is therefore to retrospectively measure the volume and percentage&#xD;
      of necrosis on diagnostic MRI in T1 sequence and in parallel to study the expression of&#xD;
      immunohistochemical markers of hypoxia (HIF-1α, CAIX , HIF-2α, pS6, phosphomTor, CD163 and&#xD;
      CD68) on diagnostic biopsies of high-grade osteosarcomas from 2007 to 2018 in the Strasbourg&#xD;
      center, focusing on the pediatric population. The investigators will systematically carry out&#xD;
      a correlation analysis between these different parameters and with the clinical data of these&#xD;
      same patients (response to chemotherapy, presence of metastases or not and overall and&#xD;
      recurrence-free survival). This will eventually make it possible to highlight new prognostic&#xD;
      markers at diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retropsective study of pediatric osteosarcomas</measure>
    <time_frame>Files analysed retrospectively from January 01, 2007 to December 31, 2018 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteosarcoma in Children</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subject ≤ 20 years having been treated for osteosarcoma in the OS2006 protocol or treated&#xD;
        according to.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject ≤ 20 years at diagnosis&#xD;
&#xD;
          -  Subject having been treated for osteosarcoma in the OS2006 protocol or treated&#xD;
             according to&#xD;
&#xD;
          -  Supported at Strasbourg University Hospitals between 05/01/2007 and 10/31/2018&#xD;
&#xD;
          -  Availability of its diagnostic tumor material stored in paraffin&#xD;
&#xD;
          -  having an MRI diagnostic evaluation comprising the injected T1 sequences necessary for&#xD;
             the analysis of the volume / necrotic proportion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition of the patient (or his legal representatives if he is a minor) to&#xD;
             participate in the study&#xD;
&#xD;
          -  Diagnosis other than osteosarcoma&#xD;
&#xD;
          -  Biological tissue from a patient who does not meet all the inclusion criteria&#xD;
&#xD;
          -  Patient under legal protection&#xD;
&#xD;
          -  Patient under guardianship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Pédiatrie Onco-hématologie - Pédiatrie III - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
    <phone>33.3.88.12.80.96</phone>
    <email>Natacha.Entz-Werle@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Pédiatrie Onco-hématologie - Pédiatrie III - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
      <phone>33 3 88 12 80 96</phone>
      <email>Natacha.Entz-Werle@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte NAZON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault WILLAUME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoît LHERMITTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François SEVERAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina PIERREVELCIN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteosarcoma</keyword>
  <keyword>Necrosis</keyword>
  <keyword>Immunohistochemical markers of hypoxia</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

